» Articles » PMID: 17296839

Differentiation Between Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis: Examination of Symptoms and Signs at Disease Onset and During Follow-up

Overview
Journal Arch Neurol
Specialty Neurology
Date 2007 Feb 14
PMID 17296839
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Motor neuron diseases can affect the upper motor neuron and/or the lower motor neuron. Both amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS) are motor neuron diseases, and there is much debate as to whether these are 2 separate disorders or simply 2 points on a continuum.

Objective: To determine which clinical features at onset and during follow-up could help differentiate between PLS and ALS.

Design: Retrospective study comparing patients with a diagnosis of PLS or ALS for differences in symptoms or signs at disease onset and during follow-up.

Setting: Tertiary referral center. Patients Six hundred sixty-one patients with ALS and 43 patients with PLS were included in the study.

Results: At presentation, stiffness was the only symptom that was significantly different between patients with PLS and patients with ALS (observed in 47% and 4% of patients, respectively; P<.001). During follow-up, limb wasting was rare in patients with PLS (2%, compared with 100% in patients with ALS; P<.001). Disease duration was significantly longer in patients with PLS compared with patients with ALS (mean +/- SD, 11.2 +/- 6.1 vs 3.8 +/- 4.2 years, respectively; P<.001). During the 16 years of follow-up, the mortality rate was significantly lower in patients with PLS compared with patients with ALS (only 33% vs 89%, respectively; P<.001).

Conclusion: Our findings suggest that a patient presenting with spasticity who does not develop wasting within 3 years most likely has PLS.

Citing Articles

Rare variant analyses validate known ALS genes in a multi-ethnic population and identifies ANTXR2 as a candidate in PLS.

Pottinger T, Motelow J, Povysil G, Moreno C, Ren Z, Phatnani H BMC Genomics. 2024; 25(1):651.

PMID: 38951798 PMC: 11218304. DOI: 10.1186/s12864-024-10538-1.


Tissue informative cell-free DNA methylation sites in amyotrophic lateral sclerosis.

Caggiano C, Morselli M, Qian X, Celona B, Thompson M, Wani S medRxiv. 2024; .

PMID: 38645132 PMC: 11030489. DOI: 10.1101/2024.04.08.24305503.


Primary Lateral Sclerosis: An Overview.

Vacchiano V, Bonan L, Liguori R, Rizzo G J Clin Med. 2024; 13(2).

PMID: 38276084 PMC: 10816328. DOI: 10.3390/jcm13020578.


Rare variant analyses validate known ALS genes in a multi-ethnic population and identifies as a candidate in PLS.

Pottinger T, Motelow J, Povysil G, Moreno C, Ren Z, Phatnani H Res Sq. 2024; .

PMID: 38196621 PMC: 10775375. DOI: 10.21203/rs.3.rs-3721598/v1.


Non-motor symptoms in motor neuron disease: prevalence, assessment and impact.

Beswick E, Forbes D, Johnson M, Newton J, Dakin R, Glasmcher S Brain Commun. 2024; 6(1):fcad336.

PMID: 38162906 PMC: 10754319. DOI: 10.1093/braincomms/fcad336.